Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Suppression of STING associated with LKB1 loss in KRAS-driven lung cancer.

Kitajima S, Ivanova E, Guo S, Yoshida R, Campisi M, Sundararaman SK, Tange S, Mitsuishi Y, Thai TC, Masuda S, Piel BP, Sholl LM, Kirschmeier PT, Paweletz CP, Watanabe H, Yajima M, Barbie DA.

Cancer Discov. 2018 Oct 8. pii: CD-18-0689. doi: 10.1158/2159-8290.CD-18-0689. [Epub ahead of print]

PMID:
30297358
2.

Success of genomic profiling of non-small cell lung cancer biopsies obtained by trans-thoracic percutaneous needle biopsy.

Gill RR, Murphy DJ, Kravets S, Sholl LM, Janne PA, Johnson BE.

J Surg Oncol. 2018 Sep 27. doi: 10.1002/jso.25241. [Epub ahead of print]

PMID:
30261097
3.

Recognizing the Challenges of Oncogene Fusion Detection: A Critical Step toward Optimal Selection of Lung Cancer Patients for Targeted Therapies.

Sholl LM.

J Thorac Oncol. 2018 Oct;13(10):1433-1435. doi: 10.1016/j.jtho.2018.08.002. No abstract available.

PMID:
30244848
4.

Reply to Petals and Thorns in Programmed Death-Ligand 1 Testing: Is All Non-Small Cell Lung Cancer Diagnostic Material Suitable?

Russell-Goldman E, Sholl LM, Vivero M.

Cancer Cytopathol. 2018 Sep 21. doi: 10.1002/cncy.22032. [Epub ahead of print] No abstract available.

PMID:
30239144
5.

Diagnostic and Predictive Immunohistochemistry for Non-Small Cell Lung Carcinomas.

Hung YP, Sholl LM.

Adv Anat Pathol. 2018 Nov;25(6):374-386. doi: 10.1097/PAP.0000000000000206.

PMID:
30188361
6.

PD-L1 Expression, Tumor Mutational Burden, and Response to Immunotherapy in Patients with MET exon 14 Altered Lung Cancers.

Sabari JK, Leonardi GC, Shu CA, Umeton R, Montecalvo J, Ni A, Chen R, Dienstag J, Mrad C, Bergagnini I, Lai WV, Offin MD, Arbour KC, Plodkowski AJ, Halpenny DF, Paik PK, Li BT, Riely GJ, Kris MG, Rudin CM, Sholl LM, Nishino M, Hellmann MD, Rekhtman N, Awad MM, Drilon A.

Ann Oncol. 2018 Aug 27. doi: 10.1093/annonc/mdy334. [Epub ahead of print]

PMID:
30165371
7.

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors.

Miao D, Margolis CA, Vokes NI, Liu D, Taylor-Weiner A, Wankowicz SM, Adeegbe D, Keliher D, Schilling B, Tracy A, Manos M, Chau NG, Hanna GJ, Polak P, Rodig SJ, Signoretti S, Sholl LM, Engelman JA, Getz G, Jänne PA, Haddad RI, Choueiri TK, Barbie DA, Haq R, Awad MM, Schadendorf D, Hodi FS, Bellmunt J, Wong KK, Hammerman P, Van Allen EM.

Nat Genet. 2018 Sep;50(9):1271-1281. doi: 10.1038/s41588-018-0200-2. Epub 2018 Aug 27.

PMID:
30150660
8.

Targeted Genomic Profiling of Female Adnexal Tumors of Probable Wolffian Origin (FATWO).

Mirkovic J, Dong F, Sholl LM, Garcia E, Lindeman N, MacConaill L, Crum CP, Nucci MR, McCluggage WG, Howitt BE.

Int J Gynecol Pathol. 2018 Aug 21. doi: 10.1097/PGP.0000000000000545. [Epub ahead of print]

PMID:
30134342
9.

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.

Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, Feeney N, Sholl LM, Dahlberg SE, Redig AJ, Kwiatkowski DJ, Rabin MS, Paweletz CP, Thress KS, Jänne PA.

JAMA Oncol. 2018 Aug 2. doi: 10.1001/jamaoncol.2018.2969. [Epub ahead of print]

PMID:
30073261
10.

Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer.

Bahcall M, Awad MM, Sholl LM, Wilson FH, Xu M, Wang S, Palakurthi S, Choi J, Ivanova EV, Leonardi GC, Ulrich BC, Paweletz CP, Kirschmeier PT, Watanabe M, Baba H, Nishino M, Nagy RJ, Lanman RB, Capelletti M, Chambers ES, Redig AJ, VanderLaan PA, Costa DB, Imamura Y, Jänne PA.

Clin Cancer Res. 2018 Aug 2. doi: 10.1158/1078-0432.CCR-18-0876. [Epub ahead of print]

PMID:
30072474
11.

Understanding patterns of pathologic response following neoadjuvant immunotherapy for solid tumors.

Sholl LM.

Ann Oncol. 2018 Aug 1;29(8):1630-1632. doi: 10.1093/annonc/mdy227. No abstract available.

PMID:
30052725
12.

Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses.

Cañadas I, Thummalapalli R, Kim JW, Kitajima S, Jenkins RW, Christensen CL, Campisi M, Kuang Y, Zhang Y, Gjini E, Zhang G, Tian T, Sen DR, Miao D, Imamura Y, Thai T, Piel B, Terai H, Aref AR, Hagan T, Koyama S, Watanabe M, Baba H, Adeni AE, Lydon CA, Tamayo P, Wei Z, Herlyn M, Barbie TU, Uppaluri R, Sholl LM, Sicinska E, Sands J, Rodig S, Wong KK, Paweletz CP, Watanabe H, Barbie DA.

Nat Med. 2018 Aug;24(8):1143-1150. doi: 10.1038/s41591-018-0116-5. Epub 2018 Jul 23.

PMID:
30038220
13.

Liquid biopsy of fine-needle aspiration supernatant for lung cancer genotyping.

Guibert N, Tsukada H, Hwang DH, Chambers E, Cibas ES, Bale T, Supplee J, Ulrich B, Sholl LM, Paweletz CP, Oxnard GR.

Lung Cancer. 2018 Aug;122:72-75. doi: 10.1016/j.lungcan.2018.05.024. Epub 2018 May 25.

PMID:
30032849
14.

Validation of a targeted next-generation sequencing approach to detect mismatch repair deficiency in colorectal adenocarcinoma.

Papke DJ Jr, Nowak JA, Yurgelun MB, Frieden A, Srivastava A, Lindeman NI, Sholl LM, MacConaill LE, Dong F.

Mod Pathol. 2018 Jun 28. doi: 10.1038/s41379-018-0091-x. [Epub ahead of print]

PMID:
29955144
15.

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.

Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, Sholl LM, Tan DSW, Wakelee HA, Wistuba II, Wynes MW, Carbone DP, Hirsch FR, Gandara DR.

J Thorac Oncol. 2018 Sep;13(9):1248-1268. doi: 10.1016/j.jtho.2018.05.030. Epub 2018 Jun 6. Review.

PMID:
29885479
16.

Immunohistochemical and molecular analysis of spitzoid neoplasms with pulverocyte subclones.

Amin SM, Haugh AM, Bubley JA, Verzì AE, Merkel EA, Lee CY, Quan VL, Garfield EM, Sholl LM, Zhang B, Gerami P.

Clin Exp Dermatol. 2018 Oct;43(7):782-789. doi: 10.1111/ced.13556. Epub 2018 May 20.

PMID:
29779219
17.

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Aguilar EJ, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV.

Cancer Discov. 2018 Jul;8(7):822-835. doi: 10.1158/2159-8290.CD-18-0099. Epub 2018 May 17.

PMID:
29773717
18.

A Disintegrin and A Metalloproteinase Domain-8 (ADAM8): A Novel Protective Proteinase in COPD.

Polverino F, Rojas-Quintero J, Wang X, Petersen H, Zhang L, Gai X, Higham A, Zhang D, Gupta K, Rout A, Yambayev I, Pinto-Plata V, Sholl LM, Cunoosamy D, Celli BR, Goldring J, Singh D, Tesfaigzi Y, Wedzicha J, Olsson H, Owen CA.

Am J Respir Crit Care Med. 2018 May 11. doi: 10.1164/rccm.201707-1331OC. [Epub ahead of print]

19.

Interpathologist Diagnostic Agreement for Non-Small Cell Lung Carcinomas Using Current and Recent Classifications.

Funkhouser WK Jr, Hayes DN, Moore DT, Funkhouser WK 3rd, Fine JP, Jo H, Nikolaishvilli-Feinberg N, Eeva M, Grilley-Olson JE, Banks PM, Graziano P, Boswell EL, Elmberger G, Raparia K, Hart CF, Sholl LM, Nolan NJ, Fritchie KJ, Pouagare E, Allen TC, Volmar KE, Biddinger PW, Kleven DT, Papez MJ, Spencer DV, Rekhtman N, Mino-Kenudson M, Hariri L, Driver B, Cagle PT.

Arch Pathol Lab Med. 2018 Apr 30. doi: 10.5858/arpa.2017-0481-OA. [Epub ahead of print]

PMID:
29708428
20.

Immunohistochemical Detection and Molecular Characterization of IDH-mutant Sinonasal Undifferentiated Carcinomas.

Mito JK, Bishop JA, Sadow PM, Stelow EB, Faquin WC, Mills SE, Krane JF, French CA, Fletcher CDM, Hornick JL, Sholl LM, Jo VY.

Am J Surg Pathol. 2018 Aug;42(8):1067-1075. doi: 10.1097/PAS.0000000000001064.

PMID:
29683816
21.

Meningioma transcription factors link cell lineage with systemic metabolic cues.

Du Z, Brewster R, Merrill PH, Chmielecki J, Francis J, Aizer A, Abedalthagafi M, Sholl LM, Geffers L, Alexander B, Santagata S.

Neuro Oncol. 2018 Sep 3;20(10):1331-1343. doi: 10.1093/neuonc/noy057.

PMID:
29660031
22.

An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib.

Abravanel DL, Nishino M, Sholl LM, Ambrogio C, Awad MM.

J Thorac Oncol. 2018 Aug;13(8):e131-e133. doi: 10.1016/j.jtho.2018.03.026. Epub 2018 Apr 6. No abstract available.

PMID:
29631033
23.

Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event.

Nishino M, Sholl LM, Awad MM, Hatabu H, Armand P, Hodi FS.

Cancer Immunol Res. 2018 Jun;6(6):630-635. doi: 10.1158/2326-6066.CIR-17-0715. Epub 2018 Apr 5.

PMID:
29622582
24.

Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.

Edelman G, Rodon J, Lager J, Castell C, Jiang J, Van Allen EM, Wagle N, Lindeman NI, Sholl LM, Shapiro GI.

Oncologist. 2018 Apr;23(4):401-e38. doi: 10.1634/theoncologist.2017-0691. Epub 2018 Mar 28.

25.

Cabozantinib in Patients with Advanced Merkel Cell Carcinoma.

Rabinowits G, Lezcano C, Catalano PJ, McHugh P, Becker H, Reilly MM, Huang J, Tyagi A, Thakuria M, Bresler SC, Sholl LM, Shapiro GI, Haddad R, DeCaprio JA.

Oncologist. 2018 Jul;23(7):814-821. doi: 10.1634/theoncologist.2017-0552. Epub 2018 Feb 14.

PMID:
29445030
26.

Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas.

Russell-Goldman E, Kravets S, Dahlberg SE, Sholl LM, Vivero M.

Cancer Cytopathol. 2018 Apr;126(4):253-263. doi: 10.1002/cncy.21973. Epub 2018 Feb 5.

PMID:
29405663
27.

Radiological features and metastatic patterns of thymic neuroendocrine tumours.

Araki T, Sholl LM, Hatabu H, Nishino M.

Clin Radiol. 2018 May;73(5):479-484. doi: 10.1016/j.crad.2017.11.025. Epub 2018 Jan 6.

PMID:
29310810
28.

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).

Aisner DL, Sholl LM, Berry LD, Rossi MR, Chen H, Fujimoto J, Moreira AL, Ramalingam SS, Villaruz LC, Otterson GA, Haura E, Politi K, Glisson B, Cetnar J, Garon EB, Schiller J, Waqar SN, Sequist LV, Brahmer J, Shyr Y, Kugler K, Wistuba II, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ; LCMC2 investigators.

Clin Cancer Res. 2018 Mar 1;24(5):1038-1047. doi: 10.1158/1078-0432.CCR-17-2289. Epub 2017 Dec 7.

PMID:
29217530
29.

Implications of the tumor immune microenvironment for staging and therapeutics.

Taube JM, Galon J, Sholl LM, Rodig SJ, Cottrell TR, Giraldo NA, Baras AS, Patel SS, Anders RA, Rimm DL, Cimino-Mathews A.

Mod Pathol. 2018 Feb;31(2):214-234. doi: 10.1038/modpathol.2017.156. Epub 2017 Dec 1. Review.

30.

Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer.

Awad MM, Mastini C, Blasco RB, Mologni L, Voena C, Mussolin L, Mach SL, Adeni AE, Lydon CA, Sholl LM, Jänne PA, Chiarle R.

Oncotarget. 2017 Sep 23;8(54):92265-92274. doi: 10.18632/oncotarget.21182. eCollection 2017 Nov 3.

31.

Targeted Genomic Profiling Reveals Recurrent KRAS Mutations in Mesonephric-like Adenocarcinomas of the Female Genital Tract.

Mirkovic J, McFarland M, Garcia E, Sholl LM, Lindeman N, MacConaill L, Dong F, Hirsch M, Nucci MR, Quick CM, Crum CP, McCluggage WG, Howitt BE.

Am J Surg Pathol. 2018 Feb;42(2):227-233. doi: 10.1097/PAS.0000000000000958.

PMID:
28984674
32.

Next-Generation Sequencing from Liquid Biopsies in Lung Cancer Patients: Advances in Comprehensive Biomarker Testing.

Sholl LM.

J Thorac Oncol. 2017 Oct;12(10):1464-1466. doi: 10.1016/j.jtho.2017.08.004. No abstract available.

33.

Histopathology of Interstitial Lung Abnormalities in the Context of Lung Nodule Resections.

Miller ER, Putman RK, Vivero M, Hung Y, Araki T, Nishino M, Washko GR, Rosas IO, Hatabu H, Sholl LM, Hunninghake GM.

Am J Respir Crit Care Med. 2018 Apr 1;197(7):955-958. doi: 10.1164/rccm.201708-1679LE. No abstract available.

PMID:
28934558
34.

Diffuse Staining for Activated NOTCH1 Correlates With NOTCH1 Mutation Status and Is Associated With Worse Outcome in Adenoid Cystic Carcinoma.

Sajed DP, Faquin WC, Carey C, Severson EA, H Afrogheh A, A Johnson C, Blacklow SC, Chau NG, Lin DT, Krane JF, Jo VY, Garcia JJ, Sholl LM, Aster JC.

Am J Surg Pathol. 2017 Nov;41(11):1473-1482. doi: 10.1097/PAS.0000000000000945.

PMID:
28914715
35.

Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care.

Nishino M, Hatabu H, Sholl LM, Ramaiya NH.

Radiographics. 2017 Sep-Oct;37(5):1371-1387. doi: 10.1148/rg.2017170015. Review.

36.

GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas.

Ritterhouse LL, Vivero M, Mino-Kenudson M, Sholl LM, Iafrate AJ, Nardi V, Dong F.

Mod Pathol. 2017 Dec;30(12):1720-1727. doi: 10.1038/modpathol.2017.88. Epub 2017 Aug 4.

PMID:
28776576
37.

The fuzzy world of precision medicine: deliberations of a precision medicine tumor board.

McGraw SA, Garber J, Jänne PA, Lindeman N, Oliver N, Sholl LM, Van Allen EM, Wagle N, Garraway LA, Joffe S, Gray SW.

Per Med. 2017 Jan;14(1):37-50. doi: 10.2217/pme-2016-0074. Epub 2016 Dec 15.

38.

Next-generation sequencing of cytologic preparations: An analysis of quality metrics.

Hwang DH, Garcia EP, Ducar MD, Cibas ES, Sholl LM.

Cancer Cytopathol. 2017 Oct;125(10):786-794. doi: 10.1002/cncy.21897. Epub 2017 Jul 20.

39.

Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society.

Thunnissen E, Allen TC, Adam J, Aisner DL, Beasley MB, Borczuk AC, Cagle PT, Capelozzi VL, Cooper W, Hariri LP, Kern I, Lantuejoul S, Miller R, Mino-Kenudson M, Radonic T, Raparia K, Rekhtman N, Roy-Chowdhuri S, Russell P, Schneider F, Sholl LM, Tsao MS, Vivero M, Yatabe Y.

Arch Pathol Lab Med. 2018 Mar;142(3):408-419. doi: 10.5858/arpa.2017-0106-SA. Epub 2017 Jul 7.

PMID:
28686497
40.

Pulmonary Clinicopathological Correlation after Allogeneic Hematopoietic Stem Cell Transplantation: An Autopsy Series.

Gazourian L, Spring L, Meserve E, Hwang D, Diaz AA, Ash SY, Ho VT, Sholl LM, Washko GR.

Biol Blood Marrow Transplant. 2017 Oct;23(10):1767-1772. doi: 10.1016/j.bbmt.2017.06.009. Epub 2017 Jun 28.

41.

Hypersensitivity Pneumonitis A Perspective From Members of the Pulmonary Pathology Society.

Miller R, Allen TC, Barrios RJ, Beasley MB, Burke L, Cagle PT, Capelozzi VL, Ge Y, Hariri LP, Kerr KM, Khoor A, Larsen BT, Mark EJ, Matsubara O, Mehrad M, Mino-Kenudson M, Raparia K, Roden AC, Russell P, Schneider F, Sholl LM, Smith ML.

Arch Pathol Lab Med. 2018 Jan;142(1):120-126. doi: 10.5858/arpa.2017-0138-SA. Epub 2017 Jun 14. Review.

PMID:
28613913
42.

Molecular and Immune Biomarkers in Acute Respiratory Distress Syndrome: A Perspective From Members of the Pulmonary Pathology Society.

Capelozzi VL, Allen TC, Beasley MB, Cagle PT, Guinee D, Hariri LP, Husain AN, Jain D, Lantuejoul S, Larsen BT, Miller R, Mino-Kenudson M, Mehrad M, Raparia K, Roden A, Schneider F, Sholl LM, Smith ML.

Arch Pathol Lab Med. 2017 Dec;141(12):1719-1727. doi: 10.5858/arpa.2017-0115-SA. Epub 2017 Jun 14. Review.

PMID:
28613912
43.

Erratum: Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2.

Zhang H, Brainson CF, Koyama S, Redig AJ, Chen T, Li S, Gupta M, Garcia-de-Alba C, Paschini M, Herter-Sprie GS, Lu G, Zhang X, Marsh BP, Tuminello SJ, Xu C, Chen Z, Wang X, Akbay EA, Zheng M, Palakurthi S, Sholl LM, Rustgi AK, Kwiatkowski DJ, Alan Diehl J, Bass AJ, Sharpless NE, Dranoff G, Hammerman PS, Ji H, Bardeesy N, Saur D, Watanabe H, Kim CF, Wong KK.

Nat Commun. 2017 Jun 9;8:15901. doi: 10.1038/ncomms15901.

44.

Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer.

Garcia EP, Minkovsky A, Jia Y, Ducar MD, Shivdasani P, Gong X, Ligon AH, Sholl LM, Kuo FC, MacConaill LE, Lindeman NI, Dong F.

Arch Pathol Lab Med. 2017 Jun;141(6):751-758. doi: 10.5858/arpa.2016-0527-OA. Epub 2017 Mar 3.

PMID:
28557599
45.

Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens.

Malapelle U, Mayo-de-Las-Casas C, Molina-Vila MA, Rosell R, Savic S, Bihl M, Bubendorf L, Salto-Tellez M, de Biase D, Tallini G, Hwang DH, Sholl LM, Luthra R, Weynand B, Vander Borght S, Missiaglia E, Bongiovanni M, Stieber D, Vielh P, Schmitt F, Rappa A, Barberis M, Pepe F, Pisapia P, Serra N, Vigliar E, Bellevicine C, Fassan M, Rugge M, de Andrea CE, Lozano MD, Basolo F, Fontanini G, Nikiforov YE, Kamel-Reid S, da Cunha Santos G, Nikiforova MN, Roy-Chowdhuri S, Troncone G; Molecular Cytopathology Meeting Group.

Cancer Cytopathol. 2017 Aug;125(8):615-626. doi: 10.1002/cncy.21868. Epub 2017 May 5.

46.

Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2.

Zhang H, Fillmore Brainson C, Koyama S, Redig AJ, Chen T, Li S, Gupta M, Garcia-de-Alba C, Paschini M, Herter-Sprie GS, Lu G, Zhang X, Marsh BP, Tuminello SJ, Xu C, Chen Z, Wang X, Akbay EA, Zheng M, Palakurthi S, Sholl LM, Rustgi AK, Kwiatkowski DJ, Diehl JA, Bass AJ, Sharpless NE, Dranoff G, Hammerman PS, Ji H, Bardeesy N, Saur D, Watanabe H, Kim CF, Wong KK.

Nat Commun. 2017 Apr 7;8:14922. doi: 10.1038/ncomms14922. Erratum in: Nat Commun. 2017 Jun 09;8:15901.

47.

Molecular Analysis of Genetic Markers for Non-Hodgkin Lymphomas.

Sholl LM, Longtine J, Kuo FC.

Curr Protoc Hum Genet. 2017 Apr 6;93:10.14.1-10.14.29. doi: 10.1002/cphg.37.

PMID:
28384399
48.

Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression.

Howitt BE, Strickland KC, Sholl LM, Rodig S, Ritterhouse LL, Chowdhury D, D'Andrea AD, Matulonis UA, Konstantinopoulos PA.

Oncoimmunology. 2017 Jan 6;6(2):e1277308. doi: 10.1080/2162402X.2016.1277308. eCollection 2017.

49.

Quantitative computed tomography assessment of bronchiolitis obliterans syndrome after lung transplantation.

Gazourian L, Ash S, Meserve EEK, Diaz A, Estepar RSJ, El-Chemaly SY, Rosas IO, Divo M, Fuhlbrigge AL, Camp PC, Ho VT, Bhatt AS, Goldberg HJ, Sholl LM, Washko GR.

Clin Transplant. 2017 May;31(5). doi: 10.1111/ctr.12943. Epub 2017 Apr 12.

50.

Genomic Characterization of Low- and High-Grade Pancreatic Mucinous Cystic Neoplasms Reveals Recurrent KRAS Alterations in "High-Risk" Lesions.

Conner JR, Mariño-Enríquez A, Mino-Kenudson M, Garcia E, Pitman MB, Sholl LM, Srivastava A, Doyle LA.

Pancreas. 2017 May/Jun;46(5):665-671. doi: 10.1097/MPA.0000000000000805.

PMID:
28196015

Supplemental Content

Loading ...
Support Center